companies developing glp-1 receptor agonists Glucagon-like Peptide-1 (GLP-1) Market Size and Evolution of GLP‐1 Receptor Agonists

The satiety effects from the GLP-1 agonist can result in an increase in insulin production along with a decrease in food consumption, appetite, and hunger, which often leads to losing weight

In clinical trials, semaglutide produced average weight losses of 12% to 15% of body weight

Devos D, Hirsch E, Wyse R

Nonetheless, although many experimental and clinical findings indicate that DPP-4 plays a role in the pathogenesis of autoimmune diseases, DPP-4 inhibition has controversial effects in autoimmune or inflammatory diseases, which might be related to the ubiquitous tissue distribution and tissue-specific regulation of DPP-4/CD26, as well as to the numerous functions and effects of DPP-4/CD26 [46]

Clarify any potential costs for medical records or administrative fees before signing

doi: 10.2337/diab.28.12.1141 172 EbertRNauckMCreutzfeldtW